{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:10:54Z","timestamp":1787728254070,"version":"build-2784847793"},"reference-count":86,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Ulcerative colitis (UC) is a chronic immune-mediated inflammatory disease characterized by substantial heterogeneity in histologic activity, which is frequently uncoupled from clinical symptoms and endoscopic findings. Persistent microscopic inflammation is increasingly recognized as a critical determinant of relapse, therapeutic failure, and long-term disease outcomes, underscoring the need for molecular frameworks that align directly with tissue-level immune dysregulation. Interleukins (ILs) represent central regulators of mucosal immunity in UC, integrating innate and adaptive immune responses that govern epithelial injury and resolution. In this narrative review, we synthesize mechanistic, translational, genetic, and clinical evidence examining IL networks associated with histologic disease activity and persistence. Particular emphasis is placed on IL-23-driven inflammatory pathways, which consistently align with histologic severity, sustained microscopic inflammation, and resistance to immune resolution. In contrast, preserved IL-10-mediated regulatory signaling characterizes histologic remission and effective mucosal healing, whereas its insufficiency permits ongoing tissue-level inflammation. Downstream effector ILs, including IL-6, IL-1\u03b2, IL-8, and IL-17A, are discussed as mediators translating upstream immune imbalance into neutrophil recruitment and epithelial injury. Throughout this review, the term \u201cprognostic\u201d is used to denote alignment with histologic disease behavior rather than validated prediction of clinical outcomes. Collectively, the evidence supports the concept that coordinated IL patterns reflect distinct immunopathologic states underlying microscopic inflammation in UC, providing a biologically coherent framework for interpreting histologic activity and disease persistence beyond symptom-based assessment.<\/jats:p>","DOI":"10.3390\/cimb48020140","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T15:41:56Z","timestamp":1769528516000},"page":"140","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Interleukin Signatures as Prognostic Biomarkers in Ulcerative Colitis: From Immune Pathways to Clinical Prediction"],"prefix":"10.3390","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6090-6076","authenticated-orcid":false,"given":"Nikolaos","family":"Martinos","sequence":"first","affiliation":[{"name":"Gastroenterology Department, Naval Hospital of Athens, 70 Dinokratous St., 11521 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8118-7780","authenticated-orcid":false,"given":"Andreas C.","family":"Lazaris","sequence":"additional","affiliation":[{"name":"First Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5876-2599","authenticated-orcid":false,"given":"Christos","family":"Kroupis","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Attikon University General Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6952-0757","authenticated-orcid":false,"given":"Georgios","family":"Kranidiotis","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Naval Hospital of Athens, 70 Dinokratous St., 11521 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia-Eleni","family":"Thomopoulou","sequence":"additional","affiliation":[{"name":"Cytopathology Department, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2249.1995.tb03721.x","article-title":"Circulating anti-inflammatory cytokine IL-10 in patients with inflammatory bowel disease","volume":"100","author":"Kucharzik","year":"1995","journal-title":"Clin. Exp. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"968","DOI":"10.3748\/wjg.v19.i7.968","article-title":"Histological healing in inflammatory bowel disease: A still unfulfilled promise","volume":"19","author":"Villanacci","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/0016-5085(95)90692-4","article-title":"Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease","volume":"108","author":"Schreiber","year":"1995","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00005-009-0031-z","article-title":"Proinflammatory cytokines and IL-10 in inflammatory bowel disease and colorectal cancer patients","volume":"57","author":"Szkaradkiewicz","year":"2009","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3748\/wjg.v10.i5.620","article-title":"IL-10 and its related cytokines for treatment of inflammatory bowel disease","volume":"10","author":"Li","year":"2004","journal-title":"World J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1136\/gutjnl-2014-309014","article-title":"Tissue-infiltrating neutrophils represent the main source of IL-23 in the colon of patients with IBD","volume":"65","author":"Kvedaraite","year":"2016","journal-title":"Gut"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1038\/ctg.2012.2","article-title":"Biomarkers of therapeutic response in the IL-23 pathway in inflammatory bowel disease","volume":"3","author":"Cayatte","year":"2012","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lucaciu, A.L., Ilie\u0219, M., Vesa, \u0218.C., Seicean, R., Din, S., Iuga, C.A., and Seicean, A. (2021). Serum interleukin (IL)-23 and IL-17 profile in inflammatory bowel disease could differentiate between severe and non-severe disease. J. Pers. Med., 11.","DOI":"10.3390\/jpm11111130"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjac034","article-title":"Interleukin-23 in the pathogenesis of inflammatory bowel disease and implications for therapeutic intervention","volume":"16","author":"Sewell","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_10","first-page":"49","article-title":"The relation between the level of interleukin-23 with duration and severity of ulcerative colitis","volume":"5","author":"Mirsattari","year":"2012","journal-title":"Gastroenterol. Hepatol. Bed Bench"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s10067-013-2469-y","article-title":"Involvement of IL-23 in enteropathic arthritis with inflammatory bowel disease","volume":"33","author":"Gheita","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/ibd.20431","article-title":"Association of IL23R, TNFRSF1A, and HLA-DRB1*0103 allele variants with inflammatory bowel disease phenotypes in the Finnish population","volume":"14","author":"Lappalainen","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Einarsdottir, E., Koskinen, L.L.E., Dukes, E., Kainu, K., Suomela, S., Lappalainen, M., Ziberna, F., Korponay-Szabo, I.R., Kurppa, K., and Kaukinen, K. (2009). IL23R in the Swedish, Finnish, Hungarian and Italian populations: Association with IBD and psoriasis, and linkage to celiac disease. BMC Med. Genet., 10.","DOI":"10.1186\/1471-2350-10-8"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/gut.2006.115402","article-title":"The IL23 axis plays a key role in the pathogenesis of IBD","volume":"56","author":"McGovern","year":"2007","journal-title":"Gut"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","article-title":"Interleukin-23 as a drug target in autoimmune inflammatory diseases","volume":"135","author":"Tang","year":"2012","journal-title":"Immunology"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Korta, A., Kula, J., and Gomu\u0142ka, K. (2023). The role of IL-23 in the pathogenesis and therapy of inflammatory bowel disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241210172"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Noviello, D., Mager, R., Roda, G., Borroni, R.G., Fiorino, G., and Vetrano, S. (2021). IL23\u2013IL17 axis in ulcerative colitis treatment: Successes and challenges. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.611256"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/ng.148","article-title":"Replication of signals from recent studies of Crohn\u2019s disease identifies previously unknown disease loci for ulcerative colitis","volume":"40","author":"Franke","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.3748\/wjg.14.5154","article-title":"Mucosal cytokine network in inflammatory bowel disease","volume":"14","author":"Andoh","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/MOG.0b013e3281c55eb2","article-title":"Immunopathogenesis of inflammatory bowel disease","volume":"23","author":"Bamias","year":"2007","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.biocel.2008.04.027","article-title":"Interleukin-23: Roles and implications","volume":"41","author":"Tan","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1600-065X.2008.00705.x","article-title":"The interleukin-23 axis in intestinal inflammation","volume":"226","author":"Ahern","year":"2008","journal-title":"Immunol. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.immuni.2006.05.017","article-title":"Differential activity of IL-12 and IL-23 in mucosal inflammation","volume":"25","author":"Uhlig","year":"2006","journal-title":"Immunity"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/ibd.20894","article-title":"Interleukin-23\/Th17 pathways and inflammatory bowel disease","volume":"15","author":"Abraham","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1136\/gut.2007.135053","article-title":"IL23 differentially regulates the Th1\/Th17 balance in ulcerative colitis and Crohn\u2019s disease","volume":"57","author":"Kobayashi","year":"2008","journal-title":"Gut"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/MCG.0b013e318074f91f","article-title":"Advanced oxidation protein products: A novel marker of oxidative stress in ulcerative colitis","volume":"42","author":"Baskol","year":"2008","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_28","first-page":"203","article-title":"Serum IL-23 and IL-17 in ulcerative colitis","volume":"27","author":"Zheng","year":"2011","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.2174\/138161210794079164","article-title":"Targeting IL-23 and Th17-cytokines in inflammatory bowel diseases","volume":"16","author":"Sarra","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1474-9726.2009.00502.x","article-title":"Aging-dependent upregulation of IL-23p19 gene expression in dendritic cells is associated with differential transcription factor binding and histone modifications","volume":"8","author":"Myer","year":"2009","journal-title":"Aging Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1572-0241.2005.40819.x","article-title":"Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-\u03b21, and IL-12p40 levels in Crohn\u2019s disease and ulcerative colitis patients in remission versus active disease","volume":"100","author":"Kader","year":"2005","journal-title":"Am. J. Gastroenterol."},{"key":"ref_32","first-page":"183","article-title":"Serum interleukin-23 levels in patients with ulcerative colitis","volume":"8","author":"Mohammadi","year":"2011","journal-title":"Iran J. Immunol."},{"key":"ref_33","first-page":"1","article-title":"IL23 as a novel serum based biomarker in ulcerative colitis\u2014An editorial","volume":"5","author":"Chakraborty","year":"2012","journal-title":"Gastroenterol. Hepatol. Bed Bench"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.coi.2006.09.008","article-title":"IL-23\/Th17 axis as therapeutic target","volume":"18","author":"Kikly","year":"2006","journal-title":"Curr. Opin. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","article-title":"IL-12, IL-23 and IL-17 in IBD: Immunobiology and therapeutic targeting","volume":"16","author":"Moschen","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/j.gastro.2016.10.018","article-title":"Lessons learned from trials targeting cytokine pathways in patients with inflammatory bowel diseases","volume":"152","author":"Abraham","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1097\/MIB.0000000000000836","article-title":"Emerging biomarkers for the diagnosis and monitoring of inflammatory bowel diseases","volume":"22","author":"Poullis","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kawashima, K., Ishihara, S., Yuki, T., Fukuba, N., Oshima, N., Kazumori, H., Sonoyama, H., Yamashita, N., Tada, Y., and Kusunoki, R. (2016). Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis. BMC Gastroenterol., 16.","DOI":"10.1186\/s12876-016-0462-z"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ajgs.2016.17","article-title":"Using markers in IBD to predict disease and treatment outcomes: Rationale and a review of current status","volume":"3","author":"Lichtenstein","year":"2016","journal-title":"Am. J. Gastroenterol. Suppl."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/j.1440-1746.2004.03486.x","article-title":"Severe ulcerative colitis: Prospective study of parameters determining outcome","volume":"19","author":"Kumar","year":"2004","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajg.2018.09.003","article-title":"Evaluation of interleukin 23 (IL-23) as a non-invasive test of disease severity in patients with ulcerative colitis","volume":"19","author":"Youssef","year":"2018","journal-title":"Arab. J. Gastroenterol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/ng.145","article-title":"Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn\u2019s disease","volume":"40","author":"Fisher","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1084\/jem.20030896","article-title":"Divergent IL-23 and IL-12 roles in autoimmunity","volume":"198","author":"Murphy","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nri1132","article-title":"The immunological and genetic basis of inflammatory bowel disease","volume":"3","author":"Bouma","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1111\/jcmm.12869","article-title":"Down-regulation of microRNAs of the miR-200 family and up-regulation of Snail and Slug in inflammatory bowel diseases\u2014Hallmark of epithelial\u2013mesenchymal transition","volume":"20","author":"Zidar","year":"2016","journal-title":"J. Cell. Mol. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000547580","article-title":"Mucosal healing of ulcerative colitis based on endoscopic diagnosis, histopathology, and mucosal inflammatory mediators","volume":"10","author":"Uchiyama","year":"2025","journal-title":"Inflamm. Intest. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/00365521.2012.758773","article-title":"Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn\u2019s disease","volume":"48","author":"Rismo","year":"2013","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"297645","DOI":"10.1155\/2009\/297645","article-title":"Interleukin-23 and Th17 cells in the control of gut inflammation","volume":"2009","author":"Monteleone","year":"2009","journal-title":"Mediat. Inflamm."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Baum, S., Hamedi, K., Loftus, C., Loftus, G., Zhou, E.-R., and Arce, S. (2025). From cytokines to biomarkers: Mapping the immunopathology of inflammatory bowel disease. Cells, 14.","DOI":"10.3390\/cells14201589"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/01.MIB.0000161917.97136.e2","article-title":"Systemic and local cytokine production in quiescent ulcerative colitis and its relationship to future relapse: A prospective pilot study","volume":"11","author":"Yamamoto","year":"2005","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1053\/gast.2000.20196","article-title":"Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn\u2019s disease: Crohn\u2019s Disease IL-10 Cooperative Study Group","volume":"119","author":"Schreiber","year":"2000","journal-title":"Gastroenterology"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Nishida, Y., Hosomi, S., Yamagami, H., Yukawa, T., Otani, K., Nagami, Y., Tanaka, F., Taira, K., Kamata, N., and Tanigawa, T. (2017). Neutrophil-to-lymphocyte ratio for predicting loss of response to infliximab in ulcerative colitis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0169845"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6572","DOI":"10.3748\/wjg.v21.i21.6572","article-title":"Effect of resveratrol on Treg\/Th17 signaling and ulcerative colitis treatment in mice","volume":"21","author":"Yao","year":"2015","journal-title":"World. J. Gastroenterol."},{"key":"ref_54","first-page":"807","article-title":"Systematic review: Histological remission in ulcerative colitis","volume":"40","author":"Bryant","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrgastro.2017.110","article-title":"The IBD interactome: An integrated view of aetiology, pathogenesis and therapy","volume":"14","author":"Fiocchi","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cytogfr.2013.11.001","article-title":"The role of transforming growth factor (TGF)-\u03b2 in modulating the immune response and fibrogenesis in the gut","volume":"25","author":"Biancheri","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bpg.2018.05.016","article-title":"Can IL-23 be a good target for ulcerative colitis?","volume":"32","author":"Allocca","year":"2018","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Kurumi, H., Yokoyama, Y., Hirano, T., Akita, K., Hayashi, Y., Kazama, T., Isomoto, H., and Nakase, H. (2024). Cytokine profile in predicting the effectiveness of advanced therapy for ulcerative colitis: A narrative review. Biomedicines, 12.","DOI":"10.3390\/biomedicines12050952"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/gut.38.1.90","article-title":"Interleukin 8: Cells of origin in inflammatory bowel disease","volume":"38","author":"Grimm","year":"1996","journal-title":"Gut"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Bertani, L., Caviglia, G.P., Antonioli, L., Pellicano, R., Fagoonee, S., Astegiano, M., Saracco, G.M., Bugianesi, E., Blandizzi, C., and Costa, F. (2020). Serum interleukin-6 and -8 as predictors of response to vedolizumab in inflammatory bowel diseases. J. Clin. Med., 9.","DOI":"10.3390\/jcm9051323"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"26875","DOI":"10.1155\/MI\/2006\/26875","article-title":"Interleukin-10 in the pathophysiology of inflammatory bowel disease: Increased serum concentrations during the recovery phase","volume":"2006","author":"Mitsuyama","year":"2006","journal-title":"Mediat. Inflamm."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"104947","DOI":"10.1016\/j.phrs.2020.104947","article-title":"Microbiota-derived butyrate regulates intestinal inflammation: Focus on inflammatory bowel disease","volume":"159","author":"Couto","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1023\/A:1005617302718","article-title":"Gut mucosal secretion of interleukin 1\u03b2 and interleukin-8 predicts relapse in clinically inactive Crohn's disease","volume":"46","author":"Arnott","year":"2001","journal-title":"Dig. Dis. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2018.12.002","article-title":"IL-23 in inflammatory bowel diseases and colon cancer","volume":"45","author":"Neurath","year":"2019","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/jgh.15813","article-title":"Mucosal interleukin-8 expression as a predictor of subsequent relapse in ulcerative colitis patients with Mayo endoscopic subscore 0","volume":"37","author":"Uchiyama","year":"2022","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.cgh.2013.02.030","article-title":"Histologic markers of inflammation in patients with ulcerative colitis in clinical remission: Correlates of histological inflammation","volume":"11","author":"Rosenberg","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Okada, T., Kanda, T., Ueda, N., Ikebuchi, Y., Hashiguchi, K., Nakao, K., and Isomoto, H. (2020). IL-8 and LYPD8 expression levels are associated with the inflammatory response in the colon of patients with ulcerative colitis. BMC Gastroenterol., 20.","DOI":"10.3892\/br.2020.1280"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/00042737-199710000-00004","article-title":"A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn\u2019s disease","volume":"9","author":"Louis","year":"1997","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.3748\/wjg.v21.i19.5823","article-title":"Contribution of the IL-17\/IL-23 axis to the pathogenesis of inflammatory bowel disease","volume":"21","author":"Cozma","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20061099","article-title":"IL-23 drives innate and T cell\u2013mediated intestinal inflammation","volume":"203","author":"Hue","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_72","first-page":"995","article-title":"Monoclonal anti\u2013IL-23 reverses active colitis","volume":"117","author":"Elson","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_73","first-page":"340","article-title":"IL-23\u2013responsive innate lymphoid cells drive intestinal pathology","volume":"477","author":"Geremia","year":"2011","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0092-8674(93)80068-P","article-title":"Interleukin-10-deficient mice develop chronic enterocolitis","volume":"75","author":"Rennick","year":"1993","journal-title":"Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nri2711","article-title":"The regulation of IL-10 production by immune cells","volume":"10","author":"Saraiva","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.immuni.2014.03.011","article-title":"IL-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function","volume":"40","author":"Shouval","year":"2014","journal-title":"Immunity"},{"key":"ref_77","first-page":"1544","article-title":"Defective IL-10 signaling defines a subset of inflammatory bowel disease","volume":"106","author":"Begue","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1056\/NEJMoa0907206","article-title":"Inflammatory bowel disease and mutations affecting the interleukin-10 receptor","volume":"361","author":"Glocker","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/75068","article-title":"Blockade of IL-6 trans-signaling suppresses colitis","volume":"6","author":"Atreya","year":"2000","journal-title":"Nat. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/ibd.20148","article-title":"IL-6 signaling in inflammatory bowel disease","volume":"13","author":"Mudter","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_81","first-page":"686","article-title":"Role of interleukin-1 in inflammatory bowel disease","volume":"98","author":"Ligumsky","year":"1990","journal-title":"Gastroenterology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/gut.38.2.216","article-title":"Increased interleukin-8 expression in ulcerative colitis","volume":"38","author":"Daig","year":"1996","journal-title":"Gut"},{"key":"ref_83","first-page":"997","article-title":"Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation","volume":"144","author":"Mazzucchelli","year":"1994","journal-title":"Am. J. Pathol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/ibd\/izy221","article-title":"An overview of molecular profiles in ulcerative colitis-related cancer","volume":"24","author":"Xue","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/01.MIB.0000437986.00190.71","article-title":"Histologic evaluation of ulcerative colitis: A systematic review of disease activity indices","volume":"20","author":"Mosli","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/gutjnl-2015-310187","article-title":"Development and validation of the Nancy histological index","volume":"66","author":"Salleron","year":"2017","journal-title":"Gut"}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/2\/140\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T16:13:01Z","timestamp":1769530381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/2\/140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":86,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["cimb48020140"],"URL":"https:\/\/doi.org\/10.3390\/cimb48020140","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]}}}